{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T04:13:47Z","timestamp":1768882427112,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T00:00:00Z","timestamp":1763164800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12185-025-04088-9","type":"journal-article","created":{"date-parts":[[2025,11,15]],"date-time":"2025-11-15T14:42:40Z","timestamp":1763217760000},"page":"127-134","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Chronic myeloid leukemia with atypical transcript e8a2: a case report and literature review"],"prefix":"10.1007","volume":"123","author":[{"given":"Xikun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jirui","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Man","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuekui","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiduo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zenghui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaohe","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,15]]},"reference":[{"key":"4088_CR1","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1002\/ajh.27443","volume":"99","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring. Am J Hematol. 2024;99:2191\u2013212.","journal-title":"Am J Hematol"},{"key":"4088_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, et al. Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2024;22:43\u201369.","journal-title":"J Natl Compr Canc Netw"},{"key":"4088_CR3","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1038\/s41375-025-02664-w","volume":"39","author":"JF Apperley","year":"2025","unstructured":"Apperley JF, Milojkovic D, Cross NCP, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797\u2013813.","journal-title":"Leukemia"},{"key":"4088_CR4","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1111\/bjh.15453","volume":"182","author":"YZ Qin","year":"2018","unstructured":"Qin YZ, Jiang Q, Jiang H, et al. Prevalence and outcomes of uncommon BCR-ABL1 fusion transcripts in patients with chronic myeloid leukaemia: data from a single centre. Br J Haematol. 2018;182:693\u2013700.","journal-title":"Br J Haematol"},{"key":"4088_CR5","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1111\/j.1365-2141.1999.01372.x","volume":"105","author":"GF How","year":"1999","unstructured":"How GF, Lim LC, Kulkarni S, et al. Two patients with novel BCR\/ABL fusion transcripts (e8\/a2 and e13\/a2) resulting from translocation breakpoints within BCR exons. Br J Haematol. 1999;105:434\u20136.","journal-title":"Br J Haematol"},{"key":"4088_CR6","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1046\/j.1365-2141.2000.02042.x","volume":"109","author":"S Branford","year":"2000","unstructured":"Branford S, Rudzki Z, Hughes TP. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. Br J Haematol. 2000;109:635\u20137.","journal-title":"Br J Haematol"},{"key":"4088_CR7","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/sj.leu.2404012","volume":"20","author":"A Tchirkov","year":"2006","unstructured":"Tchirkov A, Couderc JL, Perissel B, et al. Major molecular response to imatinib in a patient with chronic myeloid leukemia expressing a novel form of e8a2 BCR-ABL transcript. Leukemia. 2006;20:167\u20138.","journal-title":"Leukemia"},{"key":"4088_CR8","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.cancergencyto.2008.06.001","volume":"185","author":"IJ Park","year":"2008","unstructured":"Park IJ, Lim YA, Lee WG, et al. A case of chronic myelogenous leukemia with e8a2 fusion transcript. Cancer Genet Cytogenet. 2008;185:106\u20138.","journal-title":"Cancer Genet Cytogenet"},{"key":"4088_CR9","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1200\/JCO.23.01647","volume":"42","author":"FX Mahon","year":"2024","unstructured":"Mahon FX, Pfirrmann M, Dulucq S, et al. European stop tyrosine kinase inhibitor trial (EURO-SKI) in chronic myeloid leukemia: final analysis and novel prognostic factors for treatment-free remission. J Clin Oncol. 2024;42:1875\u201380.","journal-title":"J Clin Oncol"},{"key":"4088_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1159\/000178145","volume":"120","author":"YZ Qin","year":"2008","unstructured":"Qin YZ, Jiang B, Jiang Q, et al. Imatinib mesylate resistance in a chronic myeloid leukemia patient with a novel E8A2 BCR-ABL transcript variant. Acta Haematol. 2008;120:146\u20139.","journal-title":"Acta Haematol"},{"key":"4088_CR11","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1080\/10428194.2017.1323269","volume":"59","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Cheng Z, Yan WZ, et al. Molecular characterization and therapeutic reaction to dasatinib in a CML patient harboring a novel e8a2 BCR-ABL1 transcript with a somatic mutation in TP53BP2 and cadherin-10 genes. Leuk Lymphoma. 2018;59:233\u20136.","journal-title":"Leuk Lymphoma"},{"key":"4088_CR12","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000531128","volume":"146","author":"T Burmeister","year":"2023","unstructured":"Burmeister T, Bullinger L, Le Coutre P. The recurrent atypical e8a2 BCR::ABL1 transcript with insertion of an inverted 55 base pair ABL1 intron 1b sequence: a detailed molecular analysis. Acta Haematol. 2023;146:413\u20138.","journal-title":"Acta Haematol"},{"key":"4088_CR13","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s12920-022-01169-0","volume":"15","author":"A Mroczkowska","year":"2022","unstructured":"Mroczkowska A, Jazwiec B, Urbanska-Rakus J, et al. A case report of pediatric acute lymphoblastic leukemia with e8a2 BCR\/ABL1 fusion transcript. BMC Med Genomics. 2022;15:20.","journal-title":"BMC Med Genomics"},{"key":"4088_CR14","doi-asserted-by":"publisher","first-page":"919","DOI":"10.3109\/10428194.2011.555025","volume":"52","author":"SL Mccarron","year":"2011","unstructured":"Mccarron SL, Kelly J, Coen N, et al. A novel e8a2 BCR-ABL1 fusion with insertion of RALGPS1 exon 8 in a patient with relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leuk Lymphoma. 2011;52:919\u201321.","journal-title":"Leuk Lymphoma"},{"key":"4088_CR15","doi-asserted-by":"publisher","DOI":"10.5045\/kjh.2012.47.3.161","author":"MJ Kim","year":"2012","unstructured":"Kim MJ, Yoon H-J, Park TS. The e8a2 fusion transcript in B lymphoblastic leukemia withBCR-ABL1rearrangement. Korean J Hematol. 2012. https:\/\/doi.org\/10.5045\/kjh.2012.47.3.161.","journal-title":"Korean J Hematol"},{"key":"4088_CR16","doi-asserted-by":"publisher","first-page":"5237","DOI":"10.1182\/bloodadvances.2024012655","volume":"8","author":"I Matsumura","year":"2024","unstructured":"Matsumura I, Ohtake S, Atsuta Y, et al. Nilotinib vs dasatinib in achieving MR4.5 for de novo chronic myeloid leukemia: the randomized JALSG CML212 study. Blood Adv. 2024;8:5237\u201347.","journal-title":"Blood Adv"},{"key":"4088_CR17","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"JE Cortes","year":"2016","unstructured":"Cortes JE, Saglio G, Kantarjian HM, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial. J Clin Oncol. 2016;34:2333\u201340.","journal-title":"J Clin Oncol."},{"key":"4088_CR18","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"HM Kantarjian","year":"2021","unstructured":"Kantarjian HM, Hughes TP, Larson RA, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35:440\u201353.","journal-title":"Leukemia"},{"key":"4088_CR19","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.clml.2023.05.009","volume":"23","author":"G Gener-Ricos","year":"2023","unstructured":"Gener-Ricos G, Haddad FG, Sasaki K, et al. Low-dose Dasatinib (50 mg daily) frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia: 5-year follow-up results. Clin Lymphoma Myeloma Leuk. 2023;23:742\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"4088_CR20","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1111\/bjh.17654","volume":"194","author":"P Rousselot","year":"2021","unstructured":"Rousselot P, Mollica L, Guilhot J, et al. Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021;194:393\u2013402.","journal-title":"Br J Haematol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04088-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12185-025-04088-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-025-04088-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:03:02Z","timestamp":1768834982000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12185-025-04088-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,15]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["4088"],"URL":"https:\/\/doi.org\/10.1007\/s12185-025-04088-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,15]]},"assertion":[{"value":"4 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors report there are no competing interests to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical considerations for this case report have been rigorously followed, ensuring patient confidentiality and obtaining informed consent in accordance with institutional guidelines, ethical standards for medical research publication, and the principles outlined in the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participation"}},{"value":"In accordance with the journal\u2019s policies, the authors consent to the publication of this manuscript and confirm that all necessary permissions for third-party materials have been obtained. In addition, since the manuscript includes details and images of an individual, explicit consent for publication has been obtained from the individual involved.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}